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Abstract: Pluripotent stem cells can be stabilized in vitro at different developmental states by the
use of specific chemicals and soluble factors. The naïve and primed states are the best characterized
pluripotency states. Naïve pluripotent stem cells (PSCs) correspond to the early pre-implantation
blastocyst and, in mice, constitute the optimal starting state for subsequent developmental applica-
tions. However, the stabilization of human naïve PSCs remains challenging because, after short-term
culture, most current methods result in karyotypic abnormalities, aberrant DNA methylation patterns,
loss of imprinting and severely compromised developmental potency. We have recently developed
a novel method to induce and stabilize naïve human PSCs that consists in the simple addition of a
chemical inhibitor for the closely related CDK8 and CDK19 kinases (CDK8/19i). Long-term cultured
CDK8/19i-naïve human PSCs preserve their normal karyotype and do not show widespread DNA
demethylation. Here, we investigate the long-term stability of allele-specific methylation at imprinted
loci and the differentiation potency of CDK8/19i-naïve human PSCs. We report that long-term cul-
tured CDK8/19i-naïve human PSCs retain the imprinting profile of their parental primed cells, and
imprints are further retained upon differentiation in the context of teratoma formation. We have
also tested the capacity of long-term cultured CDK8/19i-naïve human PSCs to differentiate into
primordial germ cell (PGC)-like cells (PGCLCs) and trophoblast stem cells (TSCs), two cell types that
are accessible from the naïve state. Interestingly, long-term cultured CDK8/19i-naïve human PSCs
differentiated into PGCLCs with a similar efficiency to their primed counterparts. Also, long-term
cultured CDK8/19i-naïve human PSCs were able to differentiate into TSCs, a transition that was
not possible for primed PSCs. We conclude that inhibition of CDK8/19 stabilizes human PSCs in a
functional naïve state that preserves imprinting and potency over long-term culture.
Keywords: pluripotency; naïve; stem; imprinting; primordial germ cells; trophoblast; CDK8; Media-
tor; enhancers
1. Introduction
Mammalian pluripotency spans a continuum of interconvertible states, each with a
distinct set of molecular and functional attributes. Naïve pluripotency is functionally and
transcriptionally comparable to the cells of the pre-implantation epiblast [1,2], while primed
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pluripotency resembles post-implantation epiblast cells [3]. Mouse naïve pluripotency is
efficiently induced and stabilized in vitro by adding two kinase inhibitors for MEK and
GSK3 (abbreviated 2i) to the culture medium [4]. Building on the success of 2i to stabilize
naïve mouse pluripotent stem cells (PSCs), several groups have reported chemical cocktails
that include 2i and that also induce naïve-features in human PSCs [5–11]. Remarkably,
while all 2i-based cocktails for the induction of naïve human pluripotency display an
improvement in culture homogeneity, long-term expansion of human PSCs in 2i-based
naïve media results in karyotypic instability, global genomic DNA demethylation, gradual
loss of imprinting, and deficits in developmental potency [12–16]. These detrimental
effects have been attributed to the chronic inhibition of MEK, a kinase whose multiple
functions include the maintenance of DNA methylation by DNMT1 [17,18]. In support of
this, reduction of the amount of MEK inhibitor partially alleviates the genomic instability
of 2i-based naïve human PSCs [19].
Recently, we reported that the naïve state can be induced and stabilized by stimulating
the Mediator complex at enhancers through the inhibition of its kinase repression module,
composed of the highly similar kinases CDK8 and CDK19 [20,21]. We showed that the
simple addition of one chemical, a CDK8 and CDK19 inhibitor (CDK8/19i), is sufficient
to induce the primed to naïve transition in mouse and human PSCs. Interestingly, the
inhibition of CDK8 and CDK19 does not deplete genomic DNA methylation and, thereby,
does not result in karyotypic abnormalities in human PSCs [20]. Moreover, CDK8/19i-
naïve human PSCs efficiently form embryoid bodies and teratomas in mice [20], a property
that is generally compromised in 2i-naïve human PSCs [12].
Here, we assess the stability of genomic imprints after long-term culture of human
PSCs in the presence of CDK8/19i, and the capacity of CDK8/19i-treated human PSCs
to differentiate into primordial germ cell (PGC)-like cells (PGCLCs) and trophoblast stem
cells (TSCs).
2. Materials and Methods
2.1. Human PSC Resources
Human cells were obtained from commercial sources or from other academic in-
stitutions. The use of the human pluripotent stem cells employed in this study was
approved by the Spanish National Advisory Committee for Human Tissue and Cell Dona-
tion and Use and by the Catalan Department of Health (project numbers: 0336S/2473/2017;
0336/747/2018). WIBR3 and OCT4-∆PE ESCs were obtained from the laboratory of Jacob
Hanna (Weizmann Institute of Science, Rehovot, Israel). H1 ESCs, and CB5, D2#2, and
D2#4 human iPSCs were obtained from the laboratory of Nuria Montserrat (IBEC, Institute
for Bioengineering, Barcelona, Spain). H1 ESCs were bought and used in agreement with
WiCell.
2.2. Human PSC Culture Conditions
Human PSCs (hPSCs) were maintained in conventional primed conditions by culture
on growth factor-reduced phenol red-free Matrigel (Corning #356231, Corning, NY, USA) or
human ESC-qualified Matrigel (Corning #354277) with mTeSR1 media (Stem Cell Technolo-
gies). Cultures were passaged every 5–7 days manually using 0.5 µM EDTA/1xPBS (Gibco,
Grand Island, NY, USA). To reset hPSCs to CDK8/19i-naïve state, cells were maintained on
Matrigel (Corning #356231 or #354277) using mTeSR1 (Stem Cell Technologies, Vancouver,
Canada); the basal media was supplemented with 20 ng/mL of rhLIF (Peprotech, Rocky
Hill, NJ, USA) plus 0.4 µM of CNIO-CDK8/19 inhibitor (ETP-47799), as reported [20].
Differentiation of OCT4-∆PE hPSCs as control for the FACS experiments was induced with
10 µM retinoic acid (RA, Sigma, St. Louis, MO, USA) for 5 days [7].
2.3. Derivation of Primordial Germ Cells (PGCs)
For short-term pre-exposure, hPSCs were exposed for 4 days to naïve conditions. Naïve
cocktails used were: CDK8/19i [0.4 µM of CNIO-CDK8/19 inhibitor and 20 ng/mL hrLIF
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(Peprotech)], as reported [20]; or the 2i-based PXGL [1 µM PD0325901 (Axon Medchem,
Reston, VA, USA), 2 µM Gö6983 (Selleckchem, Houston, TX, USA), 2 µM XAV939 (Sell-
eckchem) and 20 ng/mL hrLIF (Peprotech)] [8]. PGCs-like derivation was performed as
previously reported [22]. Briefly, hPSCs were induced to iMeLCs (induced mesoderm-like
cells) and then into PGC-like cells. For the induction of iMeLCs, hiPSCs were plated at a
density of 5 × 104 cells/cm2 onto a fibronectin-coated (Millipore, FC010) 6-well plate in
the GK15 medium [GMEM (Thermo Fisher Scientific, Waltham, MA, USA) with 15% KSR
(Gibco), 0.1 mM NEAA (Gibco), 2 mM L-glutamine (Gibco), 1 mM sodium pyruvate (Gibco),
and 0.1 mM 2-mercaptoethanol (Gibco)] supplemented with 50 ng/mL activin A (R&D, Min-
neapolis, MN, USA), 3 µM CHIR99021 (Axon Medchem,) and 10 µM Y-27632 (Selleckchem).
After 48 h, cells (iMeLCs) were dissociated into single cells with TrypLE Select (Thermo
Fisher Scientific) and were aggregated in a low-cell-binding V-bottom 96-well plate (Thermo
Fisher Scientific, 81100574) at 3000 cells per well in the GK15 medium supplemented with
200 ng/mL BMP4 (R&D Systems), 100 ng/mL SCF (R&D Systems), 50 ng/mL EGF (R&D
Systems), 20 ng/mL hrLIF (Peprotech), and 10 µM Y-27632 to be induced into hPGCLCs.
2.4. Derivation of Trophoblast Stem Cells (TSCs)
For short-term pre-exposure, hPSCs were exposed for 4 days to naïve conditions.
Naïve cocktails used were: CDK8/19i cocktail [0.4 µM of CNIO-CDK8/19 inhibitor and
20 ng/mL hrLIF (Peprotech)], as reported [20], or the 2i-based cocktail PXGL [1 µM
PD0325901 (Axon Medchem), 2 µM Gö6983 (Selleckchem), 2 µM XAV939 (Selleckchem) and
20 ng/mL hrLIF (Peprotech)] [8]. TSCs derivation was performed as previously reported
by Kojima and colleagues [23]. Naïve and primed hPSCs were single-cell dissociated
by TrypLE Express, and 0.5 × 106 cells were seeded in a 6-well plated pre-coated with
5 mg/mL Collagen IV (#354233, Corning) and cultured in TS medium [DMEM/F12 (D6421,
Sigma), 0.1 mM 2-mercaptoethanol (Gibco), 0.2% FBS (Gibco), 0.3% BSA (Sigma), 1% ITS-X
(Gibco), 1.5 µg/mL L-ascorbic acid (Sigma), 50 ng/mL EGF (PeproTech), 2 µM CHIR99021
(Axon Medchem), 0.5 µM A83-01 (Tocris, Bristol, UK), 1 µM SB431542 (PeproTech), 0.8 mM
VPA (Sigma) and 5 µM Y-27632 (Selleckchem)] [24]. Cells were passaged every 5–7 days in
single cells using TrypLE Express on pre-coated Collagen IV plates.
2.5. Teratoma Formation Assay
Mice were housed at the specific pathogen-free (SPF) barrier area of the Institute
for Research in Biomedicine (IRB Barcelona) in Barcelona. Two injections of human H1
and D2#2 PSCs were performed per mouse in testes of SCID beige mice (8 weeks of age,
ENVIGO). 2 × 106 cells in 30 µL of mTeSR media were injected per testis. Teratomas were
extracted when reaching a size of about 1 cm.
2.6. RNA Isolation and qRT-PCR
Total RNA from cells was extracted on column by RNeasy kit with DNA digestion fol-
lowing the provider’s recommendations (Qiagen #74104, #79254, Hilden, Germany) or with
Trizol (Invitrogen, Waltham, MA, USA) according to the manufacturer’s recommendations.
Up to 1 µg of total RNA was retro-transcribed into cDNA using iScriptTM cDNA Synthesis
kit (BioRad #170-8891, Hercules, CA, USA) following the manufacturer’s protocol. Quanti-
tative real-time–PCR (qPCR) was performed using GoTaq® qPCR Master Mix (Promega
A6002) in a QuantStudio 6 Flex thermocycler (Applied Biosystem). Input normalization
of all the quantitative real-time–PCR (qRT–PCR) data was by the ∆∆Ct method using the
housekeeping gene GAPDH as indicated in each figure. Primer sequences used for mRNA
analyses are listed in Table S1.
2.7. RNA-Seq Transcriptomic Analyses
Samples of total RNA from long-term cultured (>15 passages) human PSCs (D2#2,
D2#4, H1, CB5 and WIBR3) in the absence or presence of CDK8/19i. RNA prepara-
tions with RIN numbers in the range of 9.0 to 10 (Agilent 2100 Bioanalyzer, Santa Clara,
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CA, USA) were used. For library construction 10 ng of total RNA samples were pro-
cessed with the SMART-Seq v4 Ultra Low Input RNA Kit (Clontech, Mountain View,
CA, USA), following the manufacturer’s instructions. Resulting cDNA was sheared on a
S220 Focused-ultrasonicator (Covaris, Woburn, MA, USA) and subsequently processed
with the “NEBNext Ultra II DNA Library Prep Kit for Illumina” (NEB #E7645). Briefly,
oligo(dT)-primed reverse transcription was performed in presence of a template switching
oligonucleotide, double-stranded cDNA was produced by 11 cycles of PCR and submitted
to acoustic shearing. Fragments were processed through subsequent enzymatic treatments
of end-repair, dA-tailing, and ligation to Illumina adapters. Adapter-ligated libraries were
completed by limited-cycle PCR (8 cycles). The resulting directional cDNA libraries were
sequenced for 50 bases in a single-read format, instrument: Illumina HiSeq2500 Primary
data processing: Image analysis, per-cycle base-calling and quality score assignment was
performed with Illumina Real Time Analysis software. Conversion of Illumina BCL files to
bam format was performed with the Illumina2bam tool (Wellcome Trust Sanger Institute—
NPG). The complete set of reads has been deposited in the GEO repository (accession
numbers: GSE127186 and GSE152378). Paired-end reads were aligned to the hg19 human
genome using STAR [25] with default parameters. Gene counts were computed using
the Rsubread package [26] with the inbuilt annotation for the hg19 genome. Differential
expression was performed using DESeq2 [27] using the cell line as covariate. Genes were
sorted by the shrunk fold change as computed by the “lfcShrink” function.
2.8. Differential Gene Expression Comparison of Published Studies
Gene set enrichment analysis was performed using the pre-ranked GSEA function
as implemented by the Broad Institute [28]. First, we generated two gene signatures of
differentially expressed genes (DEGs), either up-regulated or down-regulated, in short-
term cultured human PSCs (D2#2, D2#4, HERVH and H1) (raw data reported in [20]
and accessible at GSE127186). We defined gene signatures as DEGs with adjusted FDR
q-value lower than 0.1 and log2 fold changes larger than 1 (for up-regulated genes) or
lower than −0.5 (for down-regulated genes). These short-term up and down signatures
for CDK8/19i-naïve cells are in Table S2. These signatures were used to perform GSEA
against a ranked list for DEGs in the long-term cultured PSCs in the absence or presence of
CDK8/19i (n = 5 cell lines, see above RNA-seq and Table S3). As a control for other naïve
cells obtained with 2i-based cocktails, we used ranked lists of DEGs from [6,7,9,10,15,29,30],
also detailed in [20]. For the data generated in this study, genes were ranked by the shrunk
fold change as computed by the “lfcShrink” function. Gene set enrichment was run with
standard GSEA settings. Results were summarized through the Normalized Enrichment
Score (NES). Data with p < 0.05 and FDR q < 0.05 were considered significant and marked
with an asterisk (*) in the heatmap of GSEA NES scores: * p < 0.05, ** p < 0.01, *** p < 0.001.
Heatmaps were plotted using the ggplot2 package [31] in R [32].
2.9. DNA Methylation
DNA methylation analyses were performed by the laboratory of Mario Fraga (CINN,
Oviedo, Spain). DNA was purified and CpG methylation status at individual CpG sites
of DMR (Differentially Methylated Regions) regions, at imprinted genes, was assessed by
DNA bisulphite-conversion and pyrosequencing, as described [33]. DNA was purified
following the standard phenol:chloroform:isoamyl alcohol (25:24:1) (Sigma) extraction pro-
tocol. Bisulfite modification of DNA was performed with the EZ DNA Methylation-Gold
kit (#D5006, Zymo Research, Irvine, CA, USA) following the manufacturer’s instructions.
The set of primers for PCR amplification and sequencing were designed using the specific
software Pyrosequencing Assay Design (version 2.0.01.15) from Biotage AB. Primer se-
quences were designed to hybridize with CpG free sites to ensure methylation-independent
amplification, one containing a Biotin mark (Btn) at the 5′ end (Table S1). After PCR am-
plification and purification (based on the biotin mark) of the region of interest with the
specific primers, pyrosequencing was performed using PyroMark Q24 reagents, Vacuum
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Prep Workstation (Biotage AB, Uppsala, Sweden) and specific-designed sequencing primer
(Table S1). Sequencing primers were designed covering 4 or 5 CpGs per DMR. Results were
analysed with PyroMark Q24 2.0.6 (Qiagen) software and equipment, obtaining percentage
of methylation for each specific CpG site studied.
2.10. Exome Sequencing
Genomic DNA (gDNA) was purified following the manufacturer’s instructions (Qi-
agen #69504). gDNA samples were purified using AMPure DNA Magnetic Beads and
a RNASe treatment was performed on the samples. The purified gDNA was quanti-
fied using DNA Hs Qubit Assay and fragmented in 250–300 bp size using COVARIS
System. Exome capture hybridization was performed according to the manufacturer’s
instructions (AGILENT SureSelect XT Kit, Santa Clara, CA, USA), followed by Exome
capture Library preparation (NEBNext® Ultra™ DNA Library Prep Kit for Illumina, Ip-
swich, MA, USA). Next-generation sequencing was performed at HiSeq 2500 Sequenc-
ing System Illumina, Sequencing Type 125 nt Pair End. The Picard suite (Picard tools
http://broadinstitute.github.io/picard/; accessed on 30 September 2020) was used to trim
Illumina adapter. Paired-end reads were aligned to the hg19 human genome using bwa [34]
followed by removal of duplicate reads using sambamba [35]. Following the best practices
recommended by the authors of GATK [36], read quality was recalibrated (GATK version
4.0.6.0). GATK’s Haplotype caller [37] was used to discover single nucleotide and short
polymorphisms. SNPs were filtered using the following thresholds: FS > 60.0, QD < 2.0,
MQRankSum < −12.5, ReadPosRankSum < −8.0 and MQ < 40.0.
2.11. Imprinting Score
A list of putative imprinted genes was compiled from [12,14,38] and references therein.
For each gene, all SNPs passing filters were selected. For RNAseq samples corresponding to
each Exome seq sample, reads aligning to selected SNPs were counted and the percentage
of the alternative allele was computed. We filtered out positions with less than 10 reads.
Following the thresholds in [38], we defined three categories of expression depending on
the alternative allele fraction: Monoallelic 0 < AAF ≤ 0.14; Partially-monoallelic 0.15 < AFF
≤ 0.29; Biallelic 0.3 < AFF.
2.12. Statistical Analysis
For differential gene expression by RNAseq, a threshold of FDR q-value of q < 0.05, or
q < 0.01 was applied, as indicated in each case. In GSEA analysis, the standard threshold
for significance was applied, where p < 0.05 and FDR q-value < 0.05.
3. Results
3.1. CDK8/19i Stabilizes Naïve Human PSCs over Long-Term Passaging
We have previously reported that human PSCs cultured in the presence of a CDK8/19
inhibitor for about 5 to 10 passages phenocopy molecular features of naïve pluripotency
(Figure 1A) at the transcriptional, proteome, phospho-proteome and metabolome lev-
els [20,21]. Remarkably, all media cocktails based on 2i for the induction of human naïve
pluripotency result in karyotypic instability, gradual erasure of DNA methylation on im-
printed genes and deficits in developmental potency [12–16]. Published literature considers
stable long-term culture as those cultures that exceed 10 passages, and this is the time
required for the observation of karyotypic abnormalities [12,19]. Fewer passages may not
be enough to fully manifest this problem. We wondered if the CDK8/19i-naïve state can
be preserved for long periods of culture. For this, we used a reporter of the naïve state
that we had not tested previously, in particular, a reporter based on the OCT4 (also known
as POU5F1) enhancer (Figure 1B). It is well described that OCT4 expression is primarily
dependent on the proximal enhancer (PE) in primed human PSCs, while naïve human
PSCs are characterized by the predominant utilization of the distal enhancer (DE) [7,10].
After 15 passages (~90 days in culture) in the presence of CDK8/19i, human WIBR3 PSCs
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carrying the OCT4-∆PE-GFP reporter presented a substantial increase in GFP fluorescence
compared to the same cells in the absence of CDK8/19i (Figure 1C). Flow cytometry anal-
yses confirmed a substantial activation of OCT4-∆PE-GFP in CDK8/19i-cultured cells
compared to their counterparts in the absence of inhibitor (primed conditions), and com-
pared to additional negative controls consisting of retinoic acid-induced (RA) differentiated
cells and primed PSCs not carrying the reporter (Figure 1D).
To further support the stability of the naïve state in the presence of CDK8/19i, we
performed whole-transcriptome profiling on long-term (>10 passages) adapted CDK8/19i-
naïve and primed human PSCs from 5 different cell lines, namely, 3 iPSCs (CB5, D2#2, D2#4)
and 2 ESCs (WIBR3, and H1) (see Methods for accession number in public databases).
First, we observed a significant overlap between the differentially expressed genes in
short-term and long-term CDK8/19i cultures (both relative to primed cells) (Figure 1E;
see Table S4). We also asked if signatures for up-regulated and down-regulated genes
in short-term cultured CDK8/19i-naïve (relative to primed cells) (reported in [20]; see
Table S2) were enriched in the differentially expressed genes of our newly generated
transcriptomes of long-term CDK8/19i cultured cells (n = 5) (see Table S3). Importantly, the
short-term CDK8/19i naïve signatures were highly enriched in the long-term CDK8/19i-
naïve cells (Figure 1F). The short-term CDK8/19i-naïve signatures were also compared with
previously published 2i-based naïve data sets [6,7,9,10,15,29,30] and in all cases showed
high enrichment scores similar to the ones obtained with our long-term CDK8/19i-naïve
cells (Figure 1F). Therefore, we conclude that the naïve state achieved by inhibition of the
Mediator kinases CDK8/19 is stable over long-term culture.
3.2. Long-Term Preservation of Genomic Imprints in CDK8/19i-Naïve Human PSCs
Uncontrolled global DNA demethylation and loss of imprints have been reported
for all tested 2i-based naïve human PSCs [12–16]. Recent studies have shown that the
inhibition of MEK signaling is directly responsible for these undesirable effects [19,39].
Considering that CDK8/19 inhibition does not affect MEK signaling [20], we hypothesized
that long-term culture of human PSCs with CDK8/19i might preserve genomic imprinting.
First, we followed a strategy previously used based on the combination of exome
and RNA sequencing [14,38]. In particular, we performed exome sequencing of 5 human
PSCs long-term cultured (>15 passages) in the presence of CDK8/19i, and this was used to
identify SNPs in potentially imprinted genes (obtained from [14] and references therein).
Then, RNA-seq data were used to discriminate the levels of expression of each allele.
Following previous criteria [38], sites displaying 0–14% of minor allele contribution to
total gene expression were defined as monoallelic, 15–29% as partially monoallelic and
30–50% as biallelic. Only a small subset (from 9 to 13) of the potentially imprinted genes
were informative (presence of SNPs and >10 reads, see Methods) and were expressed in a
monoallelic or partially monoallelic manner in human primed PSCs. Interestingly, most
(77% to 100%) of the primed monoallelic genes remained monoallelically expressed in
long-term cultured CDK8/19i-naïve human PSCs (Figure 2A). This includes the H19/IGF2
locus, which is known to be particularly susceptible to loss of monoallelic expression in
PSCs [14,15,38].
We next assessed by pyrosequencing the methylation status of specific CpG positions
within the differentially methylated regions (DMRs) of some maternal (SNRPN) and
paternal (MEST, PEG10) imprinted loci. As expected, all the CpG positions analyzed (4 or
5 positions per DMR) were hemi-methylated in primed PSCs (Figure 2B). Interestingly,
hemi-methylation was preserved in all the long-term cultured CDK8/19i-naïve human
PSCs (Figure 2B). As a further challenge to the stability of the imprints, we injected the long-
term cultured human PSCs, both primed and naïve, into SCID mice until the formation
of teratomas. Of note, we have previously shown that long-term cultured CDK8/19i-
naïve hPSCs are capable of efficient tri-lineage teratoma formation [20]. Genomic DNA
from the teratomas was analyzed as before to determine the methylation status of DMR.
The teratomas obtained with CDK8/19i-naïve H1 cells preserved hemi-methylation at
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all the sites analyzed (Figure 2C). In the case of CDK8/19i-naïve D2#2 cells, two DMRs
lost their imprints (MEST and PEG10) and one DMR preserved hemi-methylation (SNRP)
(Figure 2C).
Figure 1. Stability of hPSC-naïve pluripotency after long-term culture with CDK8/19i. (A) Experimental scheme for
inducing naïve conditions using the previously reported CDK8/19i chemical approach [20]. (B) Schematic diagram of
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OCT4-∆PE-GFP reporter [7] for naïve human pluripotency based on the OCT4 distal enhancer (DE). (C)
Brightfield images showing colony morphology (left panels) or OCT4-∆PE-GFP expression (right panels), both
in primed (upper images) or CDK8/19i-treated (bottom images) WIBR3 reporter hESCs. (D) Comparative
fluorescent cytometry analyses of WIBR3 reporter hESCs after differentiation with retinoic acid (RA), primed
conditions, or CDK8/19i-naïve conditions, as well as the parental line WIBR3 (primed) as negative control (left
panel). Numbers indicate the % of cells in the GFP-positive gate. (E) Overlap and hypergeometric significance
of differentially expressed mRNAs in short- and long-term CDK8/19i naïve (relative to primed). (F) Heatmap
of the normalized enrichment scores (NES) of the gene-set enrichment analyses (GSEA). As signatures, we
used the differentially up- or down-regulated genes in short-term CDK8/19i-naïve (relative to primed). These
signatures were tested on the ranked lists of gene expression changes in previously published naïve conditions
(see references) and in our long-term adapted CDK8/19i hPSCs (this study). For the last comparison, we used a
total of 5 hPSCs: D2#2, D2#4, H1, CB5 and WIBR3. Statistical significance of GSEA NES scores in the heatmaps
is indicated using the symbol “*”. FDR q < 0.05; * p <0.05, ** p < 0.01, *** p < 0.001.
Altogether, we conclude that prolonged culture of PSCs in the presence of CDK8/19i
does not erase DNA methylation imprints. However, we detected some loss of imprinting
after teratoma formation. The high stability of imprinting in CDK8/19i-naïve human PSCs
is in contrast with the recent findings that >70% of imprinted DMRs were erased in 2i-based
naïve human PSCs [16].
3.3. Differentiation Potential of CDK8/19i-Naïve Human PSCs into Primordial Germ Cells
As a first test of the differentiation potential of CDK8/19i-naïve hPSCs, we examined
their capacity to generate primordial germ cell (PGC)-like cells (PGCLCs). PGCLCs have
been recently generated from human PSCs [22,40]. Here, we have employed a two-step
protocol that involves supplements to induce mesoderm-like cells (iMeLC induction)
followed by formation of embryoid bodies (EBs) in the presence of a specific PGCLC
medium (PGCLC induction) [22] (Figure 3A). These studies have shown robust production
of hPGCLCs both from primed PSCs or from PSCs briefly pre-treated for 4 days with a
2i-based cocktail known as NHSM [7].
Based on the above reports, we compared first the effect of short pre-treatments
with CDK8/19i or with another 2i-based cocktail known as PXGL [8] (Figure 3A). These
naïve pre-treatments for 4 days were sufficient to increase the mRNA levels of NANOG
in primed H1 ESCs, thereby indicating the induction of naïve features by both methods
(Figure 3B). After the short naïve pre-treatment, PGCLCs were induced according to the
protocol of Kojima et al. [22] (Figure 3A). Notably, primed and CDK8/19i-treated H1
ESCs efficiently formed EBs under PGCLC differentiation conditions (Figure 3C) and up-
regulated specific PGCLCs markers, such as CD38, PRDM1, and NANOS3 (Figure 3D).
PXGL pre-treatment was detrimental for the formation of EBs under PGCLC differentiation
conditions (Figure 3C), leading to cell death and preventing the assessment of PGCLC
markers. These results indicate that short treatment of primed PSCs with CDK8/19i does
not impair their differentiation potential into PGC-like cells.
In a subsequent set of experiments, human H1 cells that had been maintained in the
presence of CDK8/19i for more than 15 passages (p > 15) were subjected to the above-
mentioned PGCLC differentiation protocol. We were not able to obtain long-term cultures
of H1 cells in PXGL medium. Interestingly, long-term CDK8/19i-naïve cells were not
impaired in the formation of EBs under PGCLC differentiation conditions (Figure 3E) and
upregulated PGCLCs markers (CD38 and PRDM1) while downregulating the pluripotency
marker NANOG (Figure 3F). We conclude that extended treatment with CDK8/19i is not
detrimental for the differentiation capacity of PSCs into primordial germ cells.
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Figure 2. Long-term cultured CDK8/19i-naïve hPSCs retain monoallelic expression and hemi-methylation at imprinted loci.
(A) Heatmaps of allele specific expression data for the indicated informative imprinted genes in primed versus CDK8/19i
long-term cultured hPSCs. The lower part of each panel indicates the number and percentage of genes expressed in a
monoallelic or partially monoallelic manner after long-term culture in the presence of CDK8/19i. (B) CpG methylation
status of differentially methylated regions (DMRs) at the indicated imprinted loci in five hPSC lines adapted to CDK8/19i
for >10 passages. For each DMR, a total of 4 or 5 individual CpGs were analyzed by pyrosequencing. (C) CpG methylation
status of DMRs in teratomas obtained from primed hPSCs or long-term adapted to CDK8/19i.
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Figure 3. CDK8/19i-naïve hPSCs can differentiate into primordial germ cell-like cells (hPGCLCs). (A) Experimental scheme
for assessing PGC differentiation of primed, 2i (PXGL) and CDK8/19i-naïve hESCs. iMeLCs: induced mesoderm-like cells.
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(B) mRNA expression level of NANOG assessed by qRT-PCR. Up-regulation of NANOG is a feature of the naïve
state. Data represent mean ± Std Dev from 4 technical replicates. (C) Brightfield images showing H1 hESCs
before and after exposure to naïve conditions and embryoid bodies (EBs) in hPGCLCs induction conditions at
day 8. (D) mRNA expression level of selected hPGCLC markers in hESCs and EBs differentiated into hPGCLCs
assessed by qRT-PCR. Data of hESC are mean ± Std Dev from 4 technical replicates and data of hPGCLCs are
mean ± Std Dev from 4 biological replicates. (E) Brightfield images showing H1 hESCs cultured in the presence
of CDK8/19i for more than 15 passages (p > 15). Lower panel shows EB formation under PGCLC differentiation
conditions at day 8. (F) mRNA expression level of pluripotency marker NANOG and selected hPGCLC markers
in H1 cells primed or long-term cultured in CDK8/19i (more than 15 passages) before or after differentiation
into hPGCLCs assessed by qRT-PCR. Data are mean ± Std Dev from 3 biological replicates.
3.4. Differentiation Potential of CDK8/19i-Naïve Human PSCs into Trophoblast Stem Cells
Previous studies have reported that naïve human PSCs can acquire extra-embryonic
fates, and this is a distinctive property of the naïve state absent in primed PSCs [16,23].
Here, following the same strategy used above to induce PGCLC differentiation, primed
H1 and WIBR3 hESCs were briefly pre-treated for 4 days with CDK8/19i or with 2i-based
PXGL to induce naïve features (see above Figure 3B). Cells were then cultured for 20 days
in human TSC medium, as previously reported [24] (Figure 4A). In the case of WIBR3
cells, briefly-treated PXGL-naïve and CDK8/19i-naïve cells formed colonies with a typical
human TSC morphology (Figure 4B). As expected, primed WIBR3 not exposed to naïve
cocktails did not form colonies with TSC morphology (Figure 4B). In the case of H1 cells,
TSC colonies were only observed in cells briefly-treated with CDK8/19i, but not in cells
briefly-treated with PXGL for 4 days (Figure 4B). The expression of trophoblast marker
GATA3 correlated with the formation of TSC colonies, thus being maximally expressed
in cultures derived from CDK8/19i-naïve H1 and WIBR3 cells (Figure 4C). In the case of
trophoblast marker ELF5, expression was higher under TSC culture conditions but their
levels did not correlate with TSC colony formation (Figure 4C).
Finally, cells that had been maintained in the presence of CDK8/19i for more than
15 passages (p > 15) were also subjected to TSC induction. As mentioned above for PGCLC
differentiation, we were not able to obtain long-term cultures of H1 or WIBR cells in
PXGL medium. Interestingly, long-term CDK8/19i-naïve WIBR3 and H1 cells formed
colonies with distinct features of trophoblast stem cells (Figure 4D). Together, we conclude
that treatment with CDK8/19i, either short term or long term, allows hPSCs to acquire
trophoblast stem cell identity.
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Figure 4. CDK8/19i-naïve hPSCs can differentiate into trophoblast stem cells (hTSCs). (A) Experimental scheme for
assessing hTSCs differentiation of primed, 2i (PXGL) and CDK8/19i-naïve hESCs. (B) Brightfield images showing hTSC-like
colonies derived from hESCs (WIBR3 and H1) after exposure to short-term naïve conditions. (C) mRNA expression level
of selected trophoblast markers assessed by qRT-PCR. Data are mean ± Std Dev of 3 technical replicates. (D) Brightfield
images showing hTSC-like colonies derived from hESCs (WIBR3 and H1) after more than 15 passages (p > 15).
4. Discussion
This study reports three main findings regarding the ability of CDK8/19i to induce
naïve features in human PSCs. First, long-term culture (>15 passages) in the presence
of CDK8/19i maintains the expression of naïve features, as indicated by the OCT4-∆PE-
GFP reporter or global transcriptome analysis. Second, long-term CDK8/19i-naïve hPSCs
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preserve their genomic imprints intact, including hemi-methylation of differentially methy-
lated regions and monoallelic expression. Third, the naïve state induced by CDK8/19i
in hPSCs allows subsequent differentiation into primordial germ cells or into trophoblast
stem cells. Importantly, trophoblast differentiation capability is considered characteristic of
naïve hPSCs, but not primed hPSCs.
Naïve hPSCs have been previously achieved using a variety of chemical cocktails [12],
all of them based on the MEK and GK3 two inhibitors cocktail (2i) initially developed for
mouse ESCs [4]. However, 2i-based-naïve hPSCs are, in general, unstable compared to
primed hPSCs. This instability includes karyotypic abnormalities and loss of imprinted
marks [10,12,15,30]. The inhibition of MEK, a key feature of all the 2i-based cocktails, is
considered the key inducer of this genomic instability. In support of this, reduction of
the amount of MEK inhibitor in naïve cocktails reduces the accumulation of karyotypic
abnormalities [19]. The reason why MEK inhibition results in genomic instability and loss of
imprinting is not completely understood, although multiple lines of evidence implicate the
profound DNA demethylation caused by the 2i-based cocktails. During pre-implantation
embryonic stages, genomic hypomethylation is transient and genomic imprinting loci
remain protected [41]; however, in contrast, DNA hypomethylation in 2i-naïve hPSCs is not
transient and also does not replicate the embryonic demethylation patterns [15]. The role
of MEK in DNA methylation could be mediated by its stabilizing effect on UHFR1, a key
factor for the recruitment of the maintenance DNA methyltransferase DNMT1 necessary
for genomic stability and maintenance of imprinting [17,18,21,42–44].
In contrast to the above, CDK8/19 inhibition does not affect MEK activity, preserves
normal UHFR1 protein levels, does not reduce global DNA methylation and does not
result in karyotypic abnormalities even after long-term passage [20,21,44]. Given the loss
of imprinting caused by 2i-based cocktails, here we considered of interest to determine
the stability of imprinting in long-term cultured CDK8/19i-naïve hPSCs. We found that
CDK8/19i-naïve hPSCs (five different cell lines, including three iPSCs and two ESCs)
retain monoallelic expression and hemi-methylation of maternal and paternal imprinted
genes. In the case of mouse 2i-naïve PSCs, it has been reported that female cells are more
susceptible to undergo loss-of-imprinting [39,45]. In this regard, it is worth mentioning
that our five tested hPSC lines include two female cell lines, WIBR3 and CB5. Moreover,
teratomas generated from long-term CDK8/19i-naïve hPSCs also preserved most of their
tested genetic imprints. We conclude that CDK8/19i-naïve hPSCs have a high degree of
imprinting stability.
Naïve and primed hPSCs exhibit different levels of differentiation potential. Several
studies have tried to model in culture the derivation of primordial germ cell-like cells
(PGCLCs) from human PSCs [22,40,46,47]. One of these studies compared the ability to
differentiate into PGCLCs of 2i-naïve versus primed hPSCs, observing that 2i-naïve hPSCs
are more efficient in this differentiation [40]. Here, we have used the differentiation protocol
reported in [22] and we have observed that briefly-treated CDK8/19i-naïve cells are as
efficient as primed cells in activating PGCLC markers. Naïve cells are developmentally
more distant from PGCs than primed cells, however, the differentiation protocol used
does not reveal differences between the two starting PSC states. It is conceivable that the
two-step PGCLC differentiation protocol, which includes the formation of EBs, minimizes
possible kinetic differences. Interestingly, we have also observed that long-term cultured
CDK8/19i-naïve hPSCs also retain the capacity to differentiate into PGCLCs. We conclude
that the induction to CDK8/19i-naïve features in human PSCs, even after long-term culture,
does not impair their capacity to generate PGCLCs.
It has been reported that 2i-naïve human PSCs present some intrinsic plasticity to
express genes characteristic of the trophectoderm [48,49]. The study of human trophoblast
stem cells (TSCs) has been greatly accelerated thanks to the identification of culture con-
ditions for these cells [24]. Based on these sets of observations, it was found that briefly-
treated 2i-naïve hPSCs, but not primed hPSCs, can be indeed converted into TSCs [23,50].
Given that this is a differentiation assay uniquely accessible to naïve hPSCs, but not to
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primed hPSCs, we wondered if briefly-treated CDK8/19i-naïve hESCs can also differentiate
into TSCs. In fact, we observed with two hPSC lines that short treatment with CDK8/19i
allowed TSC-differentiation. Moreover, long-term treated CDK8/19i-naïve hESCs also
retained their capacity to acquire TSC identity, further corroborating the stability of the
naïve state maintained by CDK8/19 inhibition.
Taken together, we conclude that CDK8/19i-naïve cells are stable after prolonged
culture, preserving imprinting and potency, and capable of efficiently differentiating into
embryoid bodies, teratomas, primordial germ cells and trophoblast stem cells.
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in long-term human PSCs adapted to culture in Primed or CDK8/19i conditions, Table S4: DEG
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